Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 7 , ISSUE 2 ( July-December, 2018 ) > List of Articles

REVIEW ARTICLE

Advanced Cardiovascular Support in Refractory Shock

Ashwin Neelavar Udupa, Rajesh Mohan Shetty

Keywords : Hypotension, inotropes, shock, tissue perfusion, vasopressors

Citation Information : Udupa AN, Shetty RM. Advanced Cardiovascular Support in Refractory Shock. Indian J Respir Care 2018; 7 (2):67-72.

DOI: 10.4103/ijrc.ijrc_2_17

License: CC BY-NC-SA 4.0

Published Online: 02-12-2022

Copyright Statement:  Copyright © 2018; Indian Journal of Respiratory Care.


Abstract

“Shock” is a term that is used to signify inadequate tissue perfusion and cellular oxygenation. The basic principle of treating shock is restoring tissue perfusion and adequate cellular oxygenation. Resuscitation from shock is achieved using a combination of fluid therapy, inotropes, and vasopressors. Refractory shock has been defined as requirement of noradrenaline infusion of > 0.5 ìg/kg/min despite adequate volume resuscitation. Inability to use oxygen damages the cellular machinery and if not restored in time, shock can become irreversible. Mortality in these patients is very high, and the assessment and management of these patients requires a much more aggressive approach for survival. This article will focus on the management of refractory shock.


HTML PDF Share
  1. Vincent JL, De Backer D. Circulatory shock. N Engl J Med 2013;369:1726.34.
  2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017;45:486.552.
  3. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, et al. Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003;107:2313.9.
  4. Torgersen C, Dunser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: A randomized, controlled, open.label trial. Intensive Care Med 2010;36:57.65.
  5. Torgersen C, Luckner G, Schroder DC, Schmittinger CA, Rex C, Ulmer H, et al. Concomitant arginine.vasopressin and hydrocortisone therapy in severe septic shock: Association with mortality. Intensive Care Med 2011;37:1432.7.
  6. Jenkins CR, Gomersall CD, Leung P, Joynt GM. Outcome of patients receiving high dose vasopressor therapy: A retrospective cohort study. Anaesth Intensive Care 2009;37:286.9.
  7. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588.95.
  8. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003;107:2998.3002.
  9. Thiemermann C, Szabo C, Mitchell JA, Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A 1993;90:267.71.
  10. Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, et al. Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside. Intensive Care Med 2010;36:2019.29.
  11. Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta.analysis and a plea for some common sense. Crit Care Med 2013;41:1774.81.
  12. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580.637.
  13. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal.directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368.77.
  14. Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, et al. Early lactate.guided therapy in Intensive Care Unit patients: A multicenter, open.label, randomized controlled trial. Am J Respir Crit Care Med 2010;182:752.61.
  15. Singer M. Oesophageal doppler. Curr Opin Crit Care 2009;15:244.8.
  16. Marik PE, Baram M. Noninvasive hemodynamic monitoring in the Intensive Care Unit. Crit Care Clin 2007;23:383.400.
  17. Corl KA, George NR, Romanoff J, Levinson AT, Chheng DB, Merchant RC, et al. Inferior vena cava collapsibility detects fluid responsiveness among spontaneously breathing critically.ill patients. J Crit Care 2017;41:130.7.
  18. Preau S, Bortolotti P, Colling D, Dewavrin F, Colas V, Voisin B, et al. Diagnostic accuracy of the inferior vena cava collapsibility to predict fluid responsiveness in spontaneously breathing patients with sepsis and acute circulatory failure. Crit Care Med 2017;45:e290.7.
  19. Monnet X, Marik P, Teboul JL. Passive leg raising for predicting fluid responsiveness: A systematic review and meta.analysis. Intensive Care Med 2016;42:1935.47.
  20. De Backer D, Fagnoul D. Intensive care ultrasound: VI. Fluid responsiveness and shock assessment. Ann Am Thorac Soc 2014;11:129.36.
  21. Marque S, Gros A, Chimot L, Gacouin A, Lavoue S, Camus C, et al. Cardiac output monitoring in septic shock: Evaluation of the third.generation flotrac.vigileo. J Clin Monit Comput 2013;27:273.9.
  22. Argueta E, Berdine G, Pena C, Nugent KM. FloTracR monitoring system: What are its uses in critically ill medical patients? Am J Med Sci 2015;349:352.6.
  23. Zhang Z, Ni H, Qian Z. Effectiveness of treatment based on piCCO parameters in critically ill patients with septic shock and/or acute respiratory distress syndrome: A randomized controlled trial. Intensive Care Med 2015;41:444.51.
  24. Monnet X, Marik PE, Teboul JL. Prediction of fluid responsiveness: An update. Ann Intensive Care 2016;6:111.
  25. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 2014;40:1795.815.
  26. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, et al. Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock: The CRISTAL randomized trial. JAMA 2013;310:1809.17.
  27. Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: Effects on kidney function. Cochrane Database Syst Rev 2013;7:CD007594.
  28. Hollenberg SM, Parrillo JE. Acute heart failure and shock. In: Crawford MH, DeMarco J, Paulus WJ, editors. Cardiology. 3rd ed. Philadelphia: Mosby; 2010. p. 964.
  29. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs. norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial. JAMA 2016;316:509.18.
  30. Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine.resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 2003;31:1394.8.
  31. Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A, et al. Vasopressors for the treatment of septic shock: Systematic review and meta.analysis. PLoS One 2015;10:e0129305.
  32. Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32:1928.48.
  33. Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 2016;375:1638.48.
  34. Sprung CL, Goodman S, Weiss YG. Steroid therapy of septic shock. Crit Care Clin 2009;25:825.34, x.
  35. Annane D, Bellissant E, Sebille V, Lesieur O, Mathieu B, Raphael JC, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998;46:589.97.
  36. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862.71.
  37. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111.24.
  38. COIITSS Study Investigators, Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: A randomized controlled trial. JAMA 2010;303:341.8.
  39. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): A randomized, controlled pilot study. Crit Care 2009;13:R130.
  40. Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B, et al. Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med 2001;29:1860.7.
  41. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77:496.9.
  42. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017;377:419.30.
  43. Park TK, Yang JH, Jeon K, Choi SH, Choi JH, Gwon HC, et al. Extracorporeal membrane oxygenation for refractory septic shock in adults. Eur J Cardiothorac Surg 2015;47:e68.74.
  44. Takauji S, Hayakawa M, Ono K, Makise H. Respiratory extracorporeal membrane oxygenation for severe sepsis and septic shock in adults: A propensity score analysis in a multicenter retrospective observational study. Acute Med Surg 2017;4:408.17.
  45. Hiromi T, Toida C, Muguruma T, Hashiba K, Doi T, Nakamura K, et al. Two cases with intra.aortic balloon pumping use for severe septic cardiomyopathy. Acute Med Surg 2017;4:446.50.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.